Interestingly, when we divided patients into 2 groups, based on treatment escalation or not, we found a markedly significant difference in the TLs of patients on a standard regimen with biochemical and combined remission.
← all excerpts
Infliximab trough levels among patients with inflammatory bowel disease in correlation with infliximab treatment escalation: a cross-sectional study from a Greek tertiary center.
1
—
—